We use cookies for a better user experience. Read our Privacy Policy

I Agree

Acute Lymphoblastic Leukemia Market

Acute Lymphoblastic Leukemia Market (Type: B-cell Acute Lymphoblastic Leukemia and T-cell Lymphoblastic Leukemia; Treatment: Chemotherapy, Radiation Therapy, Bone Marrow Transplant, Targeted Therapy, and Immunotherapy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Acute Lymphoblastic Leukemia Market Outlook 2031

  • The global acute lymphoblastic leukemia market was valued at US$ 2.2 Bn in 2021
  • The global market is projected to grow at a CAGR of 7.6% from 2022 to 2031
  • The global acute lymphoblastic leukemia market is anticipated to reach more than US$ 4.5 Bn by the end of 2031

Analysts’ Viewpoint on Acute Lymphoblastic Leukemia Market Scenario

Rise in awareness and early detection of cancers over the last few decades has led to a decrease in mortality rate. Surge in incidence of acute lymphoblastic leukemia, increase in initiatives by public & private organizations to spread cancer awareness, rise in R&D activities for targeted therapies, and rapid technological advancements in molecular biology and pharmacology are driving the global lymphoblastic leukemia treatment market. Pharmaceutical companies are expanding their geographical footprint and launching new products through strategic collaborations with regional institutes and manufacturers. Robust pipeline of cancer drugs in early and late clinical trial phases is anticipated to provide lucrative opportunities to global manufacturers during the forecast period. Increase in number of clinical trials has paved the way for new drug approval for acute lymphoblastic leukemia treatment.

Acute Lymphoblastic Leukemia Market

Acute Lymphoblastic Leukemia Market Introduction

Acute lymphocytic leukemia (ALL), also called lympholastic leukemia, is a cancer that starts from the early version of white blood cells known as lympholastic in the bone marrow. Overproduction of cancerous lymphoblast is the primary cause of this type of cancer. When a person is suffering from ALL cancer, lymphoblasts are generally overproduced in the bone marrow and constantly multiply, causing damage to the bone marrow by restraining the production of normal cells such as platelets and red blood cells (RBC). These lymphoblasts are also called leukemia cells. As the number of lymphoblast increases in the bone marrow and blood, there is less room for healthy RBCs, white blood cells, and platelets. This could cause anemia, infection, and bleeding. The cancer can also spread to the brain and spinal cord.

Request a sample to get extensive insights into the Acute Lymphoblastic Leukemia Market

Increase in Number of Product Approvals to Drive Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market

Rise in number of product approvals for the treatment of acute lymphoblastic leukemia along with robust pipeline product in early and late phases of clinical trials is expected to propel the global acute lymphoblastic leukemia market size during the forecast period. In October 2021, Kite Pharma, Inc., a Gilead Company, announced the U.S. Food and Drug Administration (FDA) approval for Tecartus (brexucabtagene autoleucel) for the treatment of adult patients (18 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL cancer). In August 2018, Novartis AG received the European Commission approval for its CAR-T cell therapy (Kymriah) for B-cell acute lymphoblastic leukemia (ALL cancer). In August 2017, Pfizer Inc. received the U.S. FDA approval for BESPONSA (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL cancer).

Rise in Prevalence of Acute Lymphoblastic Leukemia to Propel Global Market

As per global acute lymphoblastic leukemia market trends, surge in number of patients in developing and developed countries is anticipated to increase the demand for therapeutics during the forecast period. According to the National Cancer Institute, an estimated 107,620 people were living with acute lymphocytic leukemia in the U.S. in 2019. According to a recent study, around 412,000 people worldwide are likely to be diagnosed with some type of leukemia, and acute lymphoblastic leukemia accounts for around 12% of all leukemia cases globally. Thus, rise in prevalence of acute lymphoblastic leukemia is a major factor likely to augment the global acute lymphoblastic leukemia market.

Request a custom report on Acute Lymphoblastic Leukemia Market

High Incidence Rate and New Product Approvals Fueling B-Cell Acute Lymphoblastic Leukemia Segment

In terms of type, the B-cell acute lymphoblastic leukemia segment accounted for the largest global acute lymphoblastic leukemia market share in 2021, owing to its rapid development rate in early stages and high incidence. According to the National Comprehensive Cancer Network (NCCN), B-cell ALL subtype starts in young cells that develop in the bone marrow and eventually become mature B-cells (B-lymphocytes), leading to a condition known as Burkitt type ALL (mature B-ALL). It is the most commonly occurring subtype of ALL cancer. Rapidly progressing leukemia and new product approvals are anticipated to drive the segment during the forecast period. In 2018, Novartis AG received approval for Kymriah in Japan for the treatment of B-cell acute lymphoblastic leukemia.

Usage in Acute Lymphoblastic Leukemia (ALL) Cancer Treatment Fueling Chemotherapy Segment

Based on treatment, the chemotherapy treatment segment accounted for significant share of the global market in 2021. The segment is projected to grow at a significant CAGR during the forecast period due to the high prescription rate, wide range of products, and easy availability. Chemotherapy (chemo) is the treatment of cancer with drugs. Chemotherapy drugs travel through the bloodstream to cancer cells throughout the body. This makes chemotherapy useful for cancers that have spread throughout the body, such as leukemia. Hence, chemotherapy is one of the key therapeutics used for ALL cancer treatment.

Advanced Healthcare Infrastructure Bolstering Hospitals Segment

In terms of end-user, the hospitals segment dominated the global market in 2021. The trend is likely to continue during the forecast period. This can be ascribed to the increase in health care infrastructure, favorable reimbursement policies, and surge in awareness about acute lymphoblastic leukemia. Furthermore, hospitals provide advanced medical treatment to treat acute lymphoblastic leukemia patients.

Regional Analysis of Global Acute Lymphoblastic Leukemia Market

As per global acute lymphoblastic leukemia market forecast, North America dominated the global market during the forecast period. The market in the region is driven by the increase in incidence of acute lymphoblastic leukemia, new product approvals, strong product pipeline, and rise in health care expenditure. The acute lymphoblastic leukemia market in Europe is estimated to grow at a CAGR of more than 7.3% during the forecast period. Asia Pacific is expected to be the fastest growing market for acute lymphoblastic leukemia in the next few years. Japan dominated the acute lymphoblastic leukemia market in the region in 2021. The market in India is expected to grow at a high CAGR during the forecast period.

Analysis of Key Players in Global Acute Lymphoblastic Leukemia Market

This report provides profiles of leading players operating in the global acute lymphoblastic leukemia market. These include Sanofi, Pfizer, Novartis AG, F. Hoffmann-La Roche Ltd., Erytech Pharma, Inc., Kite Pharma, Inc., Celgene Corporation, Amgen, Inc., Bristol-Myers Squibb Company, and Spectrum Pharmaceuticals, Inc. Increase in mergers & acquisitions, strategic collaborations, surge in clinical trials, and new product launches are expected to drive the global market during the forecast period. For instance, in January 2017, Novartis AG signed collaborative agreements with various key industry players to co-develop and co-commercialize oncology therapies.

Key Developments in Global Acute Lymphoblastic Leukemia Market

  • In July 2021, ERYTECH Pharma announced that the U.S. Food and Drug Administration (FDA) granted fast track designation to Eryaspase for the treatment of acute lymphocytic leukemia (ALL) patients
  • In March 2021, Amgen, Inc. announced that its immuno-oncology therapy, Blincyto, significantly prolonged event-free survival compared with consolidation chemotherapy in pediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia

Each of these players has been profiled in the acute lymphoblastic leukemia market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Acute Lymphoblastic Leukemia Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 2.2 Bn

Market Forecast Value in 2031

More than US$ 4.5 Bn

Compound Annual Growth Rate (CAGR)

7.6%

Forecast Period

2022–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Type
    • B-cell Acute Lymphoblastic Leukemia
    • T-cell Lymphoblastic Leukemia
  • Treatment
    • Chemotherapy
    • Radiation Therapy
    • Bone Marrow Transplant
    • Targeted Therapy
    • Immunotherapy
  • End-user
    • Hospitals
    • Clinics
    • Others

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Amgen, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Erytech Pharma, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Kite Pharma, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Spectrum Pharmaceuticals, Inc.

Customization Scope

Available upon request

Pricing

Available upon request

Acute Lymphoblastic Leukemia Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global acute lymphoblastic leukemia market in 2021?

The global acute lymphoblastic leukemia market was valued at US$ 2.2 Bn in 2021

How big will be the global acute lymphoblastic leukemia market in 2031?

The global market is projected to reach more than US$ 4.5 Bn by 2031

What will be the CAGR of the global acute lymphoblastic leukemia market during the forecast period (2022–2031)?

The global acute lymphoblastic leukemia market is anticipated to grow at a CAGR of 7.6% from 2022 to 2031

Which are the prominent trends that affect market growth?

Rise in prevalence of acute lymphoblastic leukemia and increase in product approvals

Who are the prominent players in the global acute lymphoblastic leukemia market?

Sanofi, Pfizer, Novartis AG, F. Hoffmann-La Roche Ltd., Erytech Pharma, Inc., Kite Pharma, Inc., Celgene Corporation, Amgen, Inc. Bristol-Myers Squibb Company, and Spectrum Pharmaceuticals, Inc.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Acute Lymphoblastic Leukemia Market

4. Market Overview

    4.1. Introduction

        4.1.1. Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Acute Lymphoblastic Leukemia Market Analysis and Forecast, 2017-2031

        4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

    5.1. Disease Prevalence & Incidence Rate globally

    5.2. Key Industry Events (mergers, acquisitions, partnerships, etc.)

    5.3. Pipeline Analysis

    5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Global Acute Lymphoblastic Leukemia Market Analysis and Forecast, by Type

    6.1. Introduction & Definition

    6.2. Key Findings/Developments

    6.3. Market Value Forecast, by Type, 2017-2031

        6.3.1. B-cell Acute Lymphoblastic Leukemia

        6.3.2. T-cell Lymphoblastic Leukemia

    6.4. Market Attractiveness Analysis, by Type

7. Global Acute Lymphoblastic Leukemia Market Analysis and Forecast, by Treatment

    7.1. Introduction & Definition

    7.2. Key Findings/Developments

    7.3. Market Value Forecast, by Treatment, 2017-2031

        7.3.1. Chemotherapy

        7.3.2. Radiation Therapy

        7.3.3. Bone Marrow Transplant

        7.3.4. Targeted Therapy

        7.3.5. Immunotherapy

    7.4. Market Attractiveness Analysis, by Treatment

8. Global Acute Lymphoblastic Leukemia Market Analysis and Forecast, by End-user

    8.1. Introduction & Definition

    8.2. Key Findings/Developments

    8.3. Market Value Forecast, by End-user, 2017-2031

        8.3.1. Hospitals

        8.3.2. Clinics

        8.3.3. Others

    8.4. Market Attractiveness Analysis, by End-user

9. Global Acute Lymphoblastic Leukemia Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region, 2017-2031

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. North America Acute Lymphoblastic Leukemia Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Type, 2017-2031

        10.2.1. B-cell Acute Lymphoblastic Leukemia

        10.2.2. T-cell Lymphoblastic Leukemia

    10.3. Market Value Forecast, by Treatment, 2017-2031

        10.3.1. Chemotherapy

        10.3.2. Radiation Therapy

        10.3.3. Bone Marrow Transplant

        10.3.4. Targeted Therapy

        10.3.5. Immunotherapy

    10.4. Market Value Forecast, by End-user, 2017-2031

        10.4.1. Hospitals

        10.4.2. Clinics

        10.4.3. Others

    10.5. Market Value Forecast, by Country, 2017-2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Type

        10.6.2. By Treatment

        10.6.3. By End-user

        10.6.4. By Country

11. Europe Acute Lymphoblastic Leukemia Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Type, 2017-2031

        11.2.1. B-cell Acute Lymphoblastic Leukemia

        11.2.2. T-cell Lymphoblastic Leukemia

    11.3. Market Value Forecast, by Treatment, 2017-2031

        11.3.1. Chemotherapy

        11.3.2. Radiation Therapy

        11.3.3. Bone Marrow Transplant

        11.3.4. Targeted Therapy

        11.3.5. Immunotherapy

    11.4. Market Value Forecast, by End-user, 2017-2031

        11.4.1. Hospitals

        11.4.2. Clinics

        11.4.3. Others

    11.5. Market Value Forecast, by Country/Sub-region, 2017-2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Type

        11.6.2. By Treatment

        11.6.3. By End-user

        11.6.4. By Country/Sub-region

12. Asia Pacific Acute Lymphoblastic Leukemia Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Type, 2017-2031

        12.2.1. B-cell Acute Lymphoblastic Leukemia

        12.2.2. T-cell Lymphoblastic Leukemia

    12.3. Market Value Forecast, by Treatment, 2017-2031

        12.3.1. Chemotherapy

        12.3.2. Radiation Therapy

        12.3.3. Bone Marrow Transplant

        12.3.4. Targeted Therapy

        12.3.5. Immunotherapy

    12.4. Market Value Forecast, by End-user, 2017-2031

        12.4.1. Hospitals

        12.4.2. Clinics

        12.4.3. Others

    12.5. Market Value Forecast, by Country/Sub-region, 2017-2031

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Type

        12.6.2. By Treatment

        12.6.3. By End-user

        12.6.4. By Country/Sub-region

13. Latin America Acute Lymphoblastic Leukemia Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Type, 2017-2031

        13.2.1. B-cell Acute Lymphoblastic Leukemia

        13.2.2. T-cell Lymphoblastic Leukemia

    13.3. Market Value Forecast, by Treatment, 2017-2031

        13.3.1. Chemotherapy

        13.3.2. Radiation Therapy

        13.3.3. Bone Marrow Transplant

        13.3.4. Targeted Therapy

        13.3.5. Immunotherapy

    13.4. Market Value Forecast, by End-user, 2017-2031

        13.4.1. Hospitals

        13.4.2. Clinics

        13.4.3. Others

    13.5. Market Value Forecast, by Country/Sub-region, 2017-2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By Type

        13.6.2. By Treatment

        13.6.3. By End-user

        13.6.4. By Country/Sub-region

14. Middle East & Africa Acute Lymphoblastic Leukemia Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Type, 2017-2031

        14.2.1. B-cell Acute Lymphoblastic Leukemia

        14.2.2. T-cell Lymphoblastic Leukemia

    14.3. Market Value Forecast, by Treatment, 2017-2031

        14.3.1. Chemotherapy

        14.3.2. Radiation Therapy

        14.3.3. Bone Marrow Transplant

        14.3.4. Targeted Therapy

        14.3.5. Immunotherapy

    14.4. Market Value Forecast, by End-user, 2017-2031

        14.4.1. Hospitals

        14.4.2. Clinics

        14.4.3. Others

    14.5. Market Value Forecast, by Country/Sub-region, 2017-2031

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Type

        14.6.2. By Treatment

        14.6.3. By End-user

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by tier and size of companies)

    15.2. Market Share Analysis, by Company, 2021

    15.3. Company Profiles

        15.3.1. Amgen, Inc.

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.1.2. Company Financials

            15.3.1.3. Growth Strategies

            15.3.1.4. SWOT Analysis

        15.3.2. Bristol-Myers Squibb Company

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.2.2. Company Financials

            15.3.2.3. Growth Strategies

            15.3.2.4. SWOT Analysis

        15.3.3. Celgene Corporation

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.3.2. Company Financials

            15.3.3.3. Growth Strategies

            15.3.3.4. SWOT Analysis

        15.3.4. Erytech Pharma, Inc.

            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.4.2. Company Financials

            15.3.4.3. Growth Strategies

            15.3.4.4. SWOT Analysis

        15.3.5. F. Hoffmann-La Roche Ltd.

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.5.2. Company Financials

            15.3.5.3. Growth Strategies

            15.3.5.4. SWOT Analysis

        15.3.6. Kite Pharma, Inc.

            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.6.2. Company Financials

            15.3.6.3. Growth Strategies

            15.3.6.4. SWOT Analysis

        15.3.7. Novartis AG

            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.7.2. Company Financials

            15.3.7.3. Growth Strategies

            15.3.7.4. SWOT Analysis

        15.3.8. Pfizer, Inc.

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.8.2. Company Financials

            15.3.8.3. Growth Strategies

            15.3.8.4. SWOT Analysis

        15.3.9. Sanofi

            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.9.2. Company Financials

            15.3.9.3. Growth Strategies

            15.3.9.4. SWOT Analysis

        15.3.10. Spectrum Pharmaceuticals, Inc.

            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.10.2. Company Financials

            15.3.10.3. Growth Strategies

            15.3.10.4. SWOT Analysis

List of Tables

Table 01: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Type, 2017–2031

Table 02: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Treatment, 2017-2031

Table 03: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by End-user, 2017–2031

Table 04: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Region, 2017–2031

Table 05: North America Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Country, 2017-2031

Table 06: North America Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Type, 2017-2031

Table 07: North America Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Treatment, 2017–2031

Table 08: North America Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by End-user, 2017-2031

Table 09: Europe Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

Table 10: Europe Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Type, 2017-2031

Table 11: Europe Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Treatment, 2017–2031

Table 12: Europe Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by End-user, 2017-2031

Table 13: Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Type, 2017-2031

Table 15: Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Treatment, 2017–2031

Table 16: Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by End-user, 2017-2031

Table 17: Latin America Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017-2031

Table 18: Latin America Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Type, 2017-2031

Table 19: Latin America Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Treatment, 2017–2031

Table 20: Latin America Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by End-user, 2017-2031

Table 21: Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Type, 2017-2031

Table 23: Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by Treatment, 2017–2031

Table 24: Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, by End-user, 2017-2031

List of Figures

Figure 01: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, 2017–2031

Figure 02: Global Acute Lymphoblastic Leukemia Market Value Share (%), by Type, 2021

Figure 03: Global Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2021

Figure 04: Global Acute Lymphoblastic Leukemia Market Value Share (%), by End-user, 2021

Figure 05: Global Acute Lymphoblastic Leukemia Market Value Share (%), by Region, 2021

Figure 06: Global Acute Lymphoblastic Leukemia Market Value Share (%), by Type, 2021 and 2031

Figure 07: Global Acute Lymphoblastic Leukemia Market Attractiveness, by Type, 2022–2031

Figure 08: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%), by B-cell, 2017-2031

Figure 09: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%), by T-cell, 2017-2031

Figure 10: Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by Treatment, 2022-2031

Figure 11: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%), by Chemotherapy, 2017-2031

Figure 12: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%), by Radiation Therapy, 2017–2031

Figure 13: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%), by Bone Marrow Transplant, 2017-2031

Figure 14: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%), by Targeted Therapy, 2017–2031

Figure 15: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%), by Immunotherapy, 2017–2031

Figure 16: Global Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Treatment, 2022-2031

Figure 17: Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2021 and 2031

Figure 18: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%), by Hospitals, 2017-2031

Figure 19: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%), by Clinics, 2017–2031

Figure 20: Global Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%), by Others, 2017–2031

Figure 21: Global Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2022–2031

Figure 22: Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by Region, 2021 and 2031

Figure 23: Global Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Region, 2022-2031

Figure 24: North America Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017–2031

Figure 25: North America Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country, 2021 and 2031

Figure 26: North America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country, 2022–2031

Figure 27: North America Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2021 and 2031

Figure 28: North America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2022–2031

Figure 29: North America Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2021 and 2031

Figure 30: North America Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2022–2031

Figure 31: North America Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2021 and 2031

Figure 32: North America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2022-2031

Figure 33: Europe Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017–2031

Figure 34: Europe Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 35: Europe Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 36: Europe Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2021 and 2031

Figure 37: Europe Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2022–2031

Figure 38: Europe Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2021 and 2031

Figure 39: Europe Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2022–2031

Figure 40: Europe Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2021 and 2031

Figure 41: Europe Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2022-2031

Figure 42: Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017–2031

Figure 43: Asia Pacific Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 44: Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 45: Asia Pacific Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2021 and 2031

Figure 46: Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2022–2031

Figure 47: Asia Pacific Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2021 and 2031

Figure 48: Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2022–2031

Figure 49: Asia Pacific Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2021 and 2031

Figure 50: Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2022-2031

Figure 51: Latin America Acute Lymphoblastic Leukemia Market Value (US$ Bn) and Y-o-Y Growth (%) Forecast, 2017–2031

Figure 52: Latin America Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 53: Latin America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 54: Latin America Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2021 and 2031

Figure 55: Latin America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2022–2031

Figure 56: Latin America Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2021 and 2031

Figure 57: Latin America Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2022–2031

Figure 58: Latin America Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2021 and 2031

Figure 59: Latin America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2022-2031

Figure 60: Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Bn) Forecast, 2017–2031

Figure 61: Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 62: Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 63: Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2021 and 2031

Figure 64: Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2022–2031

Figure 65: Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2021 and 2031

Figure 66: Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2022–2031

Figure 67: Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2021 and 2031

Figure 68: Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2022–2031

Figure 69: Global Acute Lymphoblastic Leukemia Market Share, by Company, 2021

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

617

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved